[{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Greater NY Chamber of Commerce","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Greater NY Chamber of Commerce","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Greater NY Chamber of Commerce"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Boustead Securities","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mangoceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Emifarma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"MEXICO","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Mangoceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Mangoceuticals"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clomiphene Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mangoceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Vipragen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mangoceuticals \/ Vipragen Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Mangoceuticals \/ Vipragen Biosciences"}]

Find Clinical Drug Pipeline Developments & Deals by Mangoceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : Company is evaluating a patented respiratory illness prevention technology against the H5N1 virus (Avian Influenza) infection.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 06, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Vipragen Biosciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : Mojo (enclomiphene citrate, pregnenolone and dehydroepiandrosterone) is an oral dissolvable tablet aimed at restoring hormonal balance and naturally increasing testosterone levels in men.

                          Product Name : Mojo

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 04, 2024

                          Lead Product(s) : Clomiphene Citrate,Pregnenolone,Dehydroepiandrosterone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : Emifarma will be responsible for initial development & testing of the Company’s Mango ED products a combination of Tadalafil, Oxytocin, and L-Arginine intended for Mexican and Latin American markets.

                          Product Name : Mango ED

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 12, 2024

                          Lead Product(s) : Tadalafil,Oxytocin,L-Arginine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Recipient : Emifarma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : Prime (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

                          Product Name : Prime

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 12, 2024

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : The Company intends to use the net proceeds to finance the marketing and operational expenses associated with the planned marketing of its Mango ED, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dy...

                          Product Name : Mango ED

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 15, 2023

                          Lead Product(s) : Tadalafil,Oxytocin,L-Arginine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Boustead Securities

                          Deal Size : $1.2 million

                          Deal Type : Public Offering

                          blank

                          06

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : Mango (sildenafil citrate) mango-flavored, rapid dissolve tablet is a Phosphodiesterase-5 inhibitor, which is being indicated for the treatment of erectile dysfunction.

                          Product Name : Mango

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 16, 2023

                          Lead Product(s) : Sildenafil Citrate,Oxytocin,L-Arginine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : The partnership aims bring its flagship product, Mango, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction, to New York.

                          Product Name : Mango

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 09, 2023

                          Lead Product(s) : Tadalafil,Oxytocin,L-Arginine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Greater NY Chamber of Commerce

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank